Amicus Therapeutics is a biopharmaceutical company developing novel, oral therapeutics known as pharmacological chaperones for the treatment of a range of human genetic diseases. Pharmacological chaperone technology involves the use of small molecules to restore or improve biological activity in cells by selectively binding to misfolded, unstable proteins caused by genetic mutations. This technology represents a novel, next-generation approach to the management of human genetic diseases and offers the potential to improve treatment options for many patients. Amicus is initially targeting lysosomal storage disorders, which are severe, chronic genetic diseases with unmet medical needs. The company believes pharmacological chaperone technology has broad applicability and expects to expand the portfolio to include other diseases of neurodegeneration, metabolic diseases, and oncology. Founded in 2002, Amicus has assembled an outstanding leadership team that includes scientific, medical, regulatory, and business professionals with successful track records of developing and bringing to market drugs for genetic diseases. Amicus continues to develop its pharmacological chaperone technology and has built a significant intellectual property portfolio along with its robust clinical and preclinical pipeline. Amicus has a fast-paced, high-energy, entrepreneurial team environment where employees are encouraged to be innovative and resourceful. Amicus seeks high-caliber, talented individuals with a passion to succeed.
Show more
Type
Public
HQ
Cranbury Township, US
Founded
2002
Size (employees)
263 (est)
Amicus Therapeutics was founded in 2002 and is headquartered in Cranbury Township, US
Report incorrect company information

Key People/Management at Amicus Therapeutics

William D. Chip Baird

William D. Chip Baird

Chief Financial Officer
Bradley L Campbe

Bradley L Campbe

Chief Operating Officer
Jeffrey P Castelli

Jeffrey P Castelli

Vice President
Enrique Diloné

Enrique Diloné

Vice President
Jay A Barth

Jay A Barth

Chief Medical Officer
Hung Do

Hung Do

Senior Vice President

Amicus Therapeutics Office Locations

Amicus Therapeutics has offices in Denham, Munich, Cranbury Township, Puteaux and in 1 other location
Cranbury Township, US (HQ)
1 Cedar Brook Drive
Puteaux, FR
Tour Défense 2000
Show all (5)
Report incorrect company information

Amicus Therapeutics Financials and Metrics

Amicus Therapeutics Financials

Amicus Therapeutics's revenue was reported to be $36.93 m in FY, 2017
USD

Revenue (FY, 2017)

36.9 m

Gross profit (FY, 2017)

30.7 m

Gross profit margin (FY, 2017), %

83.1%

EBIT (FY, 2017)

(442 m)

Market capitalization (23-Apr-2018)

2.1 b

Cash (31-Dec-2017)

49.1 m
Amicus Therapeutics's current market capitalization is $2.1 b.
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Revenue

122.2 m1.2 m5 m36.9 m

Revenue growth, %

(99%)(100%)

Cost of goods sold

833 k6.2 m

Gross profit

4.1 m30.7 m
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q3, 2017

Revenue

39 k456 k475 k293 k456 k475 k293 k

Cost of goods sold

344 k775 k1.8 m

General and administrative expense

4.6 m5.2 m4.8 m5.3 m6.4 m8.3 m15.4 m15.7 m19.3 m17.5 m19.1 m

R&D expense

10.1 m10 m10 m12 m16.1 m17.2 m21 m23.4 m18.3 m32.5 m30.9 m
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Cash

43.6 m24.1 m69.5 m187 m49.1 m

Accounts Receivable

1.3 m9.5 m

Inventories

5.5 m2.9 m2.6 m3.4 m4.6 m

Current Assets

88.3 m154.6 m216.6 m340.1 m392 m
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017

Cash

30 m27.5 m41.9 m19.7 m28.8 m249 m19.4 m23.5 m63.7 m33.1 m44.8 m37.4 m64.1 m

Accounts Receivable

864 k1.9 m3.8 m6 m

Inventories

194 k3.3 m3.7 m3.9 m7.3 m

Current Assets

64.3 m73.5 m79.4 m87.2 m151.3 m365 m240.1 m168.5 m217.7 m221.7 m296.2 m241 m431 m
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Net Income

(59.6 m)(68.9 m)(132.1 m)(200 m)(284 m)

Depreciation and Amortization

1.7 m1.5 m1.8 m3.2 m3.6 m

Inventories

(3.2 m)2.3 m308 k(3.7 m)(897 k)

Accounts Payable

6.2 m15.5 m7.1 m
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017

Net Income

(47.4 m)(15.9 m)(30.6 m)(47.7 m)(24.3 m)(51.4 m)(89.2 m)(43.7 m)(94.7 m)(141.4 m)(55 m)(103.1 m)(214.8 m)

Depreciation and Amortization

1.3 m412 k808 k1.2 m508 k861 k1.3 m673 k1.4 m2.3 m823 k1.6 m

Inventories

(207 k)(3.5 m)(243 k)(351 k)7.3 m

Accounts Payable

(679 k)(987 k)(155 k)1.2 m(551 k)459 k14.1 m(9.8 m)(8.2 m)(2.9 m)(1.3 m)
USDY, 2017

Revenue/Employee

140.4 k

Financial Leverage

1.8 x
Show all financial metrics
Report incorrect company information